Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study

Kosei Doshita; Tateaki Naito; Suguru Matsuda; Meiko Morita; Motoki Sekikawa; Keita Miura; Hiroaki Kodama; Michitoshi Yabe; Noboru Morikawa; Yuko Iida; Nobuaki Mamesaya; Haruki Kobayashi; Ryo Ko; Kazushige Wakuda; Akira Ono; Haruyasu Murakami; Hirotsugu Kenmotsu; Toshiaki Takahashi

doi:10.1111/1759-7714.15403

Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study

Kosei Doshita, Tateaki Naito, Suguru Matsuda, Meiko Morita, Motoki Sekikawa, Keita Miura, Hiroaki Kodama, Michitoshi Yabe, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Haruyasu Murakami, Hirotsugu Kenmotsu, Toshiaki Takahashi

Shizuoka Cancer Center

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Chemotherapy-induced anorexia is a common occurrence in patients undergoing treatment for advanced lung cancer. However, the relationship between chemotherapy-induced anorexia and weight loss during platinum-based chemotherapy combined with immune checkpoint inhibitors is unclear. This study explored the relationship between chemotherapy-induced anorexia and therapeutic outcomes in patients with stage IV non-small-cell lung cancer undergoing platinum-based chemotherapy combined with immune checkpoint inhibitors. Methods: The study retrospectively reviewed the medical records of 106 patients with stage IV non-small-cell lung cancer treated with platinum-based chemotherapy and immune checkpoint inhibitors between January 2019 and October 2022. The incidence of weight loss and its association with treatment efficacy was assessed in the chemotherapy-induced anorexia group. Chemotherapy-induced anorexia, nausea, and vomiting were evaluated using Common Terminology Criteria for Adverse Events v 5.0. Progression-free and overall survival were used to measure treatment efficacy. Results: Chemotherapy-induced anorexia was observed in 13.2% of patients. These patients exhibited significant weight loss at 6 and 9 weeks after treatment initiation compared to those in the non-chemotherapy-induced anorexia group. Progression-free and overall survival were shorter in the chemotherapy-induced anorexia group than in the non-chemotherapy-induced anorexia group, but the difference was not statistically significant. Conclusions: Chemotherapy-induced anorexia was associated with significant weight loss and reduced treatment efficacy in patients with stage IV non-small-cell lung cancer. These results highlight the importance of implementing robust supportive care for chemotherapy-induced anorexia to mitigate weight loss and uphold treatment effectiveness during platinum-based chemotherapy combined with immune checkpoint inhibitors.

Original language	English
Pages (from-to)	1831-1841
Number of pages	11
Journal	Thoracic Cancer
Volume	15
Issue number	25
DOIs	https://doi.org/10.1111/1759-7714.15403
Publication status	Published - Sept 2024
Externally published	Yes

Keywords

anorexia
chemotherapy
immune checkpoint inhibitors
non-small cell lung cancer
treatment efficacy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/1759-7714.15403

Cite this

Doshita, K., Naito, T., Matsuda, S., Morita, M., Sekikawa, M., Miura, K., Kodama, H., Yabe, M., Morikawa, N., Iida, Y., Mamesaya, N., Kobayashi, H., Ko, R., Wakuda, K., Ono, A., Murakami, H., Kenmotsu, H., & Takahashi, T. (2024). Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study. Thoracic Cancer, 15(25), 1831-1841. https://doi.org/10.1111/1759-7714.15403

@article{ddf7303bc552438a94e16dc9c3a2fcaf,

title = "Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study",

abstract = "Background: Chemotherapy-induced anorexia is a common occurrence in patients undergoing treatment for advanced lung cancer. However, the relationship between chemotherapy-induced anorexia and weight loss during platinum-based chemotherapy combined with immune checkpoint inhibitors is unclear. This study explored the relationship between chemotherapy-induced anorexia and therapeutic outcomes in patients with stage IV non-small-cell lung cancer undergoing platinum-based chemotherapy combined with immune checkpoint inhibitors. Methods: The study retrospectively reviewed the medical records of 106 patients with stage IV non-small-cell lung cancer treated with platinum-based chemotherapy and immune checkpoint inhibitors between January 2019 and October 2022. The incidence of weight loss and its association with treatment efficacy was assessed in the chemotherapy-induced anorexia group. Chemotherapy-induced anorexia, nausea, and vomiting were evaluated using Common Terminology Criteria for Adverse Events v 5.0. Progression-free and overall survival were used to measure treatment efficacy. Results: Chemotherapy-induced anorexia was observed in 13.2% of patients. These patients exhibited significant weight loss at 6 and 9 weeks after treatment initiation compared to those in the non-chemotherapy-induced anorexia group. Progression-free and overall survival were shorter in the chemotherapy-induced anorexia group than in the non-chemotherapy-induced anorexia group, but the difference was not statistically significant. Conclusions: Chemotherapy-induced anorexia was associated with significant weight loss and reduced treatment efficacy in patients with stage IV non-small-cell lung cancer. These results highlight the importance of implementing robust supportive care for chemotherapy-induced anorexia to mitigate weight loss and uphold treatment effectiveness during platinum-based chemotherapy combined with immune checkpoint inhibitors.",

keywords = "anorexia, chemotherapy, immune checkpoint inhibitors, non-small cell lung cancer, treatment efficacy",

author = "Kosei Doshita and Tateaki Naito and Suguru Matsuda and Meiko Morita and Motoki Sekikawa and Keita Miura and Hiroaki Kodama and Michitoshi Yabe and Noboru Morikawa and Yuko Iida and Nobuaki Mamesaya and Haruki Kobayashi and Ryo Ko and Kazushige Wakuda and Akira Ono and Haruyasu Murakami and Hirotsugu Kenmotsu and Toshiaki Takahashi",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Thoracic Cancer published by John Wiley & Sons Australia, Ltd.",

year = "2024",

month = sep,

doi = "10.1111/1759-7714.15403",

language = "English",

volume = "15",

pages = "1831--1841",

journal = "Thoracic Cancer",

issn = "1759-7706",

publisher = "Blackwell Publishing Asia Pty Ltd",

number = "25",

}

Doshita, K, Naito, T, Matsuda, S, Morita, M, Sekikawa, M, Miura, K, Kodama, H, Yabe, M, Morikawa, N, Iida, Y, Mamesaya, N, Kobayashi, H, Ko, R, Wakuda, K, Ono, A, Murakami, H, Kenmotsu, H & Takahashi, T 2024, 'Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study', Thoracic Cancer, vol. 15, no. 25, pp. 1831-1841. https://doi.org/10.1111/1759-7714.15403

TY - JOUR

T1 - Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment

T2 - a retrospective study

AU - Doshita, Kosei

AU - Naito, Tateaki

AU - Matsuda, Suguru

AU - Morita, Meiko

AU - Sekikawa, Motoki

AU - Miura, Keita

AU - Kodama, Hiroaki

AU - Yabe, Michitoshi

AU - Morikawa, Noboru

AU - Iida, Yuko

AU - Mamesaya, Nobuaki

AU - Kobayashi, Haruki

AU - Ko, Ryo

AU - Wakuda, Kazushige

AU - Ono, Akira

AU - Murakami, Haruyasu

AU - Kenmotsu, Hirotsugu

AU - Takahashi, Toshiaki

PY - 2024/9

Y1 - 2024/9

N2 - Background: Chemotherapy-induced anorexia is a common occurrence in patients undergoing treatment for advanced lung cancer. However, the relationship between chemotherapy-induced anorexia and weight loss during platinum-based chemotherapy combined with immune checkpoint inhibitors is unclear. This study explored the relationship between chemotherapy-induced anorexia and therapeutic outcomes in patients with stage IV non-small-cell lung cancer undergoing platinum-based chemotherapy combined with immune checkpoint inhibitors. Methods: The study retrospectively reviewed the medical records of 106 patients with stage IV non-small-cell lung cancer treated with platinum-based chemotherapy and immune checkpoint inhibitors between January 2019 and October 2022. The incidence of weight loss and its association with treatment efficacy was assessed in the chemotherapy-induced anorexia group. Chemotherapy-induced anorexia, nausea, and vomiting were evaluated using Common Terminology Criteria for Adverse Events v 5.0. Progression-free and overall survival were used to measure treatment efficacy. Results: Chemotherapy-induced anorexia was observed in 13.2% of patients. These patients exhibited significant weight loss at 6 and 9 weeks after treatment initiation compared to those in the non-chemotherapy-induced anorexia group. Progression-free and overall survival were shorter in the chemotherapy-induced anorexia group than in the non-chemotherapy-induced anorexia group, but the difference was not statistically significant. Conclusions: Chemotherapy-induced anorexia was associated with significant weight loss and reduced treatment efficacy in patients with stage IV non-small-cell lung cancer. These results highlight the importance of implementing robust supportive care for chemotherapy-induced anorexia to mitigate weight loss and uphold treatment effectiveness during platinum-based chemotherapy combined with immune checkpoint inhibitors.

AB - Background: Chemotherapy-induced anorexia is a common occurrence in patients undergoing treatment for advanced lung cancer. However, the relationship between chemotherapy-induced anorexia and weight loss during platinum-based chemotherapy combined with immune checkpoint inhibitors is unclear. This study explored the relationship between chemotherapy-induced anorexia and therapeutic outcomes in patients with stage IV non-small-cell lung cancer undergoing platinum-based chemotherapy combined with immune checkpoint inhibitors. Methods: The study retrospectively reviewed the medical records of 106 patients with stage IV non-small-cell lung cancer treated with platinum-based chemotherapy and immune checkpoint inhibitors between January 2019 and October 2022. The incidence of weight loss and its association with treatment efficacy was assessed in the chemotherapy-induced anorexia group. Chemotherapy-induced anorexia, nausea, and vomiting were evaluated using Common Terminology Criteria for Adverse Events v 5.0. Progression-free and overall survival were used to measure treatment efficacy. Results: Chemotherapy-induced anorexia was observed in 13.2% of patients. These patients exhibited significant weight loss at 6 and 9 weeks after treatment initiation compared to those in the non-chemotherapy-induced anorexia group. Progression-free and overall survival were shorter in the chemotherapy-induced anorexia group than in the non-chemotherapy-induced anorexia group, but the difference was not statistically significant. Conclusions: Chemotherapy-induced anorexia was associated with significant weight loss and reduced treatment efficacy in patients with stage IV non-small-cell lung cancer. These results highlight the importance of implementing robust supportive care for chemotherapy-induced anorexia to mitigate weight loss and uphold treatment effectiveness during platinum-based chemotherapy combined with immune checkpoint inhibitors.

KW - anorexia

KW - chemotherapy

KW - immune checkpoint inhibitors

KW - non-small cell lung cancer

KW - treatment efficacy

UR - http://www.scopus.com/inward/record.url?scp=85200005392&partnerID=8YFLogxK

U2 - 10.1111/1759-7714.15403

DO - 10.1111/1759-7714.15403

M3 - Article

C2 - 39075850

AN - SCOPUS:85200005392

SN - 1759-7706

VL - 15

SP - 1831

EP - 1841

JO - Thoracic Cancer

JF - Thoracic Cancer

IS - 25

ER -

Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this